What is it about?

In our study exploring HIV treatment in India, we looked at how well a medication called DTG works and whether it's safe for people living with HIV. We found that DTG effectively reduces the amount of virus in the body and is generally safe for most people. One interesting finding was that some participants experienced weight gain, especially those who were sicker at the beginning of treatment. While this weight gain could be a sign of improving health, we need to study it further to understand its effects better. Overall, DTG appears to be a promising option for HIV treatment in India.

Featured Image

Why is it important?

This study on DTG in HIV treatment is crucial for India and beyond. It offers insights into effective and safe therapies, empowering healthcare providers to tailor treatments for better outcomes. The discovery of weight gain as a potential side effect adds depth to our understanding, prompting further exploration for comprehensive care. These findings not only impact patient well-being but also shape public health strategies to combat HIV globally.

Perspectives

This study highlights DTG's effectiveness and safety in HIV treatment in India, addressing key gaps in real-world evaluation. With strong virological suppression and minimal adverse events, DTG emerges as a promising first- and second-line option. The observed weight gain and metabolic changes offer valuable insights for tailored patient management, setting a benchmark for future research and enhancing HIV care strategies.

Dr. Nishant Raman

Read the Original

This page is a summary of: A Phase-IV Non-interventional Study to Assess Virological Effectiveness, Safety, and Tolerability of DTG-based Antiretroviral Therapy in HIV-1 Infected Indian Persons Living with HIV, Current HIV Research, January 2024, Bentham Science Publishers,
DOI: 10.2174/011570162x264021231108010324.
You can read the full text:

Read

Resources

Contributors

The following have contributed to this page